Top Markets
Coin of the day
Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.

ANTH
Rank in Stocks #42276
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on... Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.62K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Anthera Pharmaceuticals, Inc. (ANTH)

Category

Earnings for Anthera Pharmaceuticals, Inc. (ANTH)
Earnings in 2026 TTM: 0
According to Anthera Pharmaceuticals, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Anthera Pharmaceuticals, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR